US20020169182A1 - Neurotrophin antagonist compositions - Google Patents
Neurotrophin antagonist compositions Download PDFInfo
- Publication number
- US20020169182A1 US20020169182A1 US09/758,917 US75891701A US2002169182A1 US 20020169182 A1 US20020169182 A1 US 20020169182A1 US 75891701 A US75891701 A US 75891701A US 2002169182 A1 US2002169182 A1 US 2002169182A1
- Authority
- US
- United States
- Prior art keywords
- isoquinoline
- dioxo
- tetrahydrobenzo
- loweralkyl
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 67
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000005557 antagonist Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 230000000694 effects Effects 0.000 claims abstract description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 20
- -1 benzimidaz-2-yl Chemical group 0.000 claims abstract description 19
- 238000001727 in vivo Methods 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 150000001408 amides Chemical class 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 5
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims description 42
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 25
- 210000002569 neuron Anatomy 0.000 claims description 20
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- XNPLAGSBSNNWSD-UHFFFAOYSA-N (1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl) acetate Chemical compound C1=CC=C2C=CC=CC32C1CC(=O)N(OC(=O)C)C3=O XNPLAGSBSNNWSD-UHFFFAOYSA-N 0.000 claims description 8
- BSMLNRFWSYKIEP-UHFFFAOYSA-N 2-(dimethylamino)-5-nitro-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O BSMLNRFWSYKIEP-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- FOHVEYFTPNIRHA-UHFFFAOYSA-N 2-(2-aminophenyl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound NC1=CC=CC=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O FOHVEYFTPNIRHA-UHFFFAOYSA-N 0.000 claims description 6
- LIMGTTOBSVFWHF-UHFFFAOYSA-N 6-phenylsulfanyl-2-(2-pyridin-2-ylethyl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C2C=CC=CC32C(=O)N(CCC=2N=CC=CC=2)C(=O)CC3C=C1SC1=CC=CC=C1 LIMGTTOBSVFWHF-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- HFCAHBWZCRSZEE-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=CC=C2NC(N3C(=O)C45C=CC=CC5=CC=CC4CC3=O)=NC2=C1 HFCAHBWZCRSZEE-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- VCICXIUPVYISNU-UHFFFAOYSA-N n-[2-(1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O VCICXIUPVYISNU-UHFFFAOYSA-N 0.000 claims description 4
- 229910000071 diazene Inorganic materials 0.000 claims description 3
- OUBANBKTBRGNLP-UHFFFAOYSA-N 3-(1-morpholin-4-yl-5-nitro-2,3,4,4a-tetrahydrobenzo[i]isoquinolin-1-yl)-3-oxopropanal Chemical compound [O-][N+](=O)C1=CC=C2C=CC=CC22C1CCNC2(C(=O)CC=O)N1CCOCC1 OUBANBKTBRGNLP-UHFFFAOYSA-N 0.000 claims description 2
- XQFSDWLIFRTQQP-UHFFFAOYSA-N 6-bromo-2-(dimethylamino)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C(Br)C=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O XQFSDWLIFRTQQP-UHFFFAOYSA-N 0.000 claims description 2
- VXAXIJJDWCWXRI-UHFFFAOYSA-N C1=CC=C2C(=O)NC(=O)C3=C2C1=CC([N+]([O-])=O)=C3C(C)(C)CC(=O)OC Chemical compound C1=CC=C2C(=O)NC(=O)C3=C2C1=CC([N+]([O-])=O)=C3C(C)(C)CC(=O)OC VXAXIJJDWCWXRI-UHFFFAOYSA-N 0.000 claims description 2
- PCHTYOFNOJYYNQ-UHFFFAOYSA-N C1=CC=C2C=CC=CC32C1CC(=O)N(CC)C3=O Chemical compound C1=CC=C2C=CC=CC32C1CC(=O)N(CC)C3=O PCHTYOFNOJYYNQ-UHFFFAOYSA-N 0.000 claims description 2
- HEJDFHJICJPEMK-UHFFFAOYSA-N n-[2-(1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl)-4,5-dimethylphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC(C)=C(C)C=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O HEJDFHJICJPEMK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000014511 neuron projection development Effects 0.000 abstract description 6
- 230000004770 neurodegeneration Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 229940053128 nerve growth factor Drugs 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 208000004454 Hyperalgesia Diseases 0.000 description 11
- 108090000099 Neurotrophin-4 Proteins 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- 0 [1*]N1C(=O)C2=CC([2*])=C([3*])/C3=C/C=C\C(=C23)C1=O Chemical compound [1*]N1C(=O)C2=CC([2*])=C([3*])/C3=C/C=C\C(=C23)C1=O 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004230 Neurotrophin 3 Human genes 0.000 description 5
- 108090000742 Neurotrophin 3 Proteins 0.000 description 5
- 102000003683 Neurotrophin-4 Human genes 0.000 description 5
- 102100033857 Neurotrophin-4 Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 229940032018 neurotrophin 3 Drugs 0.000 description 5
- 229940097998 neurotrophin 4 Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108090000095 Neurotrophin-6 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- PQOCKZOSEFVARA-UHFFFAOYSA-N 1h-benzo[i]isoquinoline Chemical compound C1=CC=CC23CN=CC=C3C=CC=C21 PQOCKZOSEFVARA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 102000015533 trkA Receptor Human genes 0.000 description 3
- 108010064884 trkA Receptor Proteins 0.000 description 3
- UGCGNTGOSOAMPN-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-benzo[i]isoquinoline Chemical compound C1=CC=C2C=CC=CC32C1CCNC3 UGCGNTGOSOAMPN-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101150111783 NTRK1 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002248 primary sensory neuron Anatomy 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 102000015534 trkB Receptor Human genes 0.000 description 2
- 108010064880 trkB Receptor Proteins 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- DYWWDZQRZYAPHQ-UHFFFAOYSA-N 3-benzoyl-4-ethyl-4-methyl-2-phenyl-1,3-oxazolidin-5-one Chemical compound O1C(=O)C(CC)(C)N(C(=O)C=2C=CC=CC=2)C1C1=CC=CC=C1 DYWWDZQRZYAPHQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- HMUJXBDVINRXTR-UHFFFAOYSA-N CC(C)(C)CCNCCN(C(c1cccc2cccc3c12)=O)C3=O Chemical compound CC(C)(C)CCNCCN(C(c1cccc2cccc3c12)=O)C3=O HMUJXBDVINRXTR-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- GRSMWKLPSNHDHA-UHFFFAOYSA-N Naphthalic anhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=CC3=C1 GRSMWKLPSNHDHA-UHFFFAOYSA-N 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- HVSBYTYZNPAFDV-UHFFFAOYSA-N O=C(c1cccc2cccc3c12)N(CS)C3=O Chemical compound O=C(c1cccc2cccc3c12)N(CS)C3=O HVSBYTYZNPAFDV-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- YRRFBANPGRXQNJ-UHFFFAOYSA-M acetyl(trimethyl)azanium;bromide Chemical compound [Br-].CC(=O)[N+](C)(C)C YRRFBANPGRXQNJ-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 108010063338 receptorphin Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 102000047459 trkC Receptor Human genes 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to neurotrophin antagonists.
- the present invention relates to compositions comprising an effective amount of a compound which inhibits or reduces undesirable neurotrophin activity, and a pharmaceutically acceptable carrier.
- the family of neurotrophins includes the nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5) and neurotrophin-6 (NT-6).
- NGF nerve growth factor
- BDNF brain-derived neurotrophic factor
- NT-3 neurotrophin-3
- NT-4 neurotrophin-4
- NT-5 neurotrophin-5
- NT-6 neurotrophin-6
- the neurotrophins exhibit similar structural conformations, including three surface ⁇ -hairpin loops, a ⁇ -strand, an internal reverse turn region, and N- and C-termini. With respect to sequence similarities, the neurotrophins share approximately 50% amino acid identity.
- the neurotrophins are also functionally similar in that they each exhibit low affinity binding to a receptor known as the “p75 nerve growth factor receptor” or p75 NGFR .
- Each neurotrophin also exhibits binding to a receptor of the tyrosine kinase (trk) family which is of higher affinity than the binding to the p75 receptor. This interaction is believed to be related to neuron survival, but is also involved with neuron differentiation including process formation.
- trk tyrosine kinase
- the trk receptor-neurotrophin interaction has been found to be more selective than neurotrophin interaction with the p75 NGFR receptor.
- NGF binds only a trk receptor known as the TrkA receptor, while BDNF, NT-4 and NT-5 exhibit exclusive binding to a TrkB receptor.
- TrkA receptor a trk receptor known as the TrkA receptor
- BDNF, NT-4 and NT-5 exhibit exclusive binding to a TrkB receptor.
- NT-3 is less selective and, although it binds primarily with a TrkC receptor, it also exhibits some binding to the TrkA and TrkB receptors (Ibanez et al., EMBO J. 1993, 12:2281).
- the neurotrophins function primarily to promote survival of certain classes of peripheral and central neurons both during development and following neuronal damage.
- NGF in particular, is involved with the development of neurons in the peripheral nervous system and supports neuronal survival, as well as enhancing and maintaining the differentiated state of neurons.
- the neurotrophins may also support inappropriate neurite outgrowth thereby facilitating the progression of a disease condition.
- neurotrophins promote the undesirable sprouting of hippocampal “mossy fibres”. Such inappropriate sprouting of mossy fibres is a common accompaniment of epilepsy in humans.
- the pain experienced by patients suffering from some chronic pain syndromes may be associated with sprouting of sensory pain fibers responsive to NGF in particular into the spinal cord.
- NGF neurotrophic growth factor
- neurotrophins are essential for the normal development and growth of neurons, they may be detrimental under certain circumstances.
- ligands capable of inhibiting or reducing selected neurotrophin-mediated activities would be desirable therapeutically to treat neurodegenerative diseases and conditions including neuropathic pain and to repair nervous system injury.
- compositions capable of inhibiting, or at least reducing, undesirable neurotrophin-mediated activity.
- composition which comprises a carrier and an effective amount of a compound of Formula I:
- R 1 is selected from alkyl; aryl-loweralkyl; heterocycle-loweralkyl; loweralkyl-carbonate; amino optionally monosubstituted or disubstituted with a substituent selected from loweralkyl, aryl and hydroxyloweralkyl; benzimidaz-2-yl;
- R 4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; NHCH 2 CH 2 OX wherein X represents an in vivo hydrolyzable ester; and loweralkyl-(R 5 )(R 6 ) wherein one of R 5 and R 6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; and R 2 and R 3 are independently selected from H, NO 2 , halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S—, loweralkyl, and Z(O)OR 7 wherein Z is selected from C and S and R 7 is selected from H, loweralkylamino
- a method for inhibiting a neurotrophin-mediated activity comprising the step of exposing neurons to a composition as described above.
- a further aspect of the present invention provides a method for inhibiting neurotrophin-mediated activity in a mammal comprising the step of administering a composition as described above to said mammal.
- alkyl as used herein means straight and branched chain alkyl radicals containing from one to eight carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl, pentyl, hexyl, heptyl, octyl and the like.
- loweralkyl as used herein means straight and branched chain alkyl radicals containing from one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, tert-butyl and the like.
- alkoxy as used herein means straight and branched chain alkoxy radicals containing from one to eight carbon atoms and includes methoxy, ethoxy, tert-butoxy and the like.
- loweralkoxy as used herein means straight and branched chain alkoxy radicals containing from one to four carbon atoms and includes methoxy, ethoxy, tert-butoxy and the like.
- aryl as used herein means a 5 or 6 membered aromatic or heteroaromatic ring containing 1, 2 or 3 heteroatoms independently selected from O, N and S, and includes phenyl, pyridyl, thienyl, furanyl, pyrrolo, imidazolo and the like.
- heterocycle means a five or six membered, non-aromatic ring optionally containing one or more double bonds and one or two heteroatoms selected from O, S, and N, and includes dihydropyran, tetrahydropyran, tetrahydrofuranyl, azacyclohexane, azacyclohexene, dihydrothiapyran, tetrahydrothiapyran, morpholino and the like.
- halo as used herein means halide and includes fluoro, chloro, bromo and iodo.
- hydrolyzable esters or amides are those readily hydrolyzable esters or amides of compounds of Formula I, which are known and used in the pharmaceutical industry and include ⁇ -acyloxyalkyl and esters of C 3-20 -fatty acids.
- neurotrophin refers to neurotrophic factors that are structurally homologous to NGF, i.e. include three surface ⁇ -hairpin loops, a ⁇ -strand, an internal reverse turn region, and N- and C-termini, and which promote at least one of neuron survival and neuron differentiation, as determined using assays of conventional design such as the in vitro assay exemplified herein and described by Riopelle et al. in Can. J. of Phys. and Pharm., 1982, 60:707.
- Mammalian nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5) and neurotrophin-6 (NT-6) are examples of neurotrophins.
- Neurotrophin-mediated activity is a biological activity that is normally promoted, either directly or indirectly, in the presence of a neurotrophin.
- Neurotrophin-mediated activities include, for example, neurotrophin binding to the p75 NGFR receptor or neurotrophin binding to one of the trk receptors, neuron survival, neuron differentiation including neuron process formation and neurite outgrowth, and biochemical changes such as enzyme induction.
- a biological activity that is mediated by a particular neurotrophin, e.g. NGF is referred to herein by reference to that neurotrophin, e.g. NGF-mediated activity.
- conventional in vitro and in vivo assays can be used.
- a receptor binding assay such as the assay described herein in Example 1, can be used to assess the extent to which a compound inhibits neurotrophin/receptor binding. Inhibition of neurite survival and outgrowth can be determined using the in vitro assay described by Riopelle et al. in the Can. J. of Phys. and Pharm., 1982, 60:707, illustrated herein in Example 2.
- the present invention relates to compositions comprising an effective amount of a compound of Formula I, or pharmaceutically acceptable salts or in vivo hydrolyzable esters or amides thereof (hereinafter referred to as a compound of Formula I), which inhibits neurotrophin-mediated activity, and a pharmaceutically acceptable carrier.
- a compound of Formula I or pharmaceutically acceptable salts or in vivo hydrolyzable esters or amides thereof (hereinafter referred to as a compound of Formula I), which inhibits neurotrophin-mediated activity, and a pharmaceutically acceptable carrier.
- compounds of Formula I include those in which R 1 is selected from alkyl; aryl-loweralkyl; heterocycle-loweralkyl; loweralkyl-carbonate; amino optionally monosubstituted or disubstituted with a substituent selected from loweralkyl, aryl and hydroxyloweralkyl; benzimidaz-2-yl;
- R 4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; NHCH 2 CH 2 OX wherein X represents an in vivo hydrolyzable ester; and loweralkyl-(R 5 )(R 6 ) wherein one of R 5 and R 6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; and R 2 and R 3 are independently selected from H, NO 2 , halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S—, loweralkyl, and Z(O)OR 7 wherein Z is selected from C and S and R 7 is selected from H, loweralkylamino
- compounds of Formula I include those in which R 1 is selected from aryl-loweralkyl; heterocycle-loweralkyl; loweralkyl-carbonate; amino optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and hydroxyloweralkyl; benzimidaz-2-yl; NHCH 2 CH 2 OX wherein X represents an in vivo hydrolyzable ester; and loweralkyl-(R 5 )(R 6 ) wherein one of R 5 and R 6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; and R 2 and R 3 are independently selected from H, NO 2 , di(loweralkyl)amino, and phenyl-S—; and pharmaceutically acceptable salts thereof.
- compounds of Formula I include those in which R 1 is selected from amino optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and hydroxyloweralkyl; NHCH 2 CH 2 OX wherein X represents an in vivo hydrolyzable ester; and loweralkyl-(R 5 )(R 6 ) wherein one of R 5 and R 6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; and R 2 and R 3 are independently selected from H and NO 2 ; and pharmaceutically acceptable salts thereof.
- compounds of Formula I include:
- N-Anilino-1,8-naphthalimide N-Anilino-1,8-naphthalimide.
- compounds of Formula I include:
- compounds of Formula I include:
- compounds of Formula I include:
- Another embodiment of the invention includes an in vivo hydrolyzable ester or amide of a compound selected from the group consisting of:
- the compounds of the present invention can be prepared by techniques well known in the art.
- Compounds of formula I wherein R 1 , R 2 and R 3 are as defined above can be prepared by reacting a 1,8-naphthalic anhydride of Formula A with a primary amine of Formula B in a suitable solvent such as toluene, methanol, ethanol, propanol or acetone and at temperatures in the range of 0° C. to the boiling point of the solvent used.
- a suitable solvent such as toluene, methanol, ethanol, propanol or acetone
- Acid addition salts of the compounds of Formula I are most suitably formed from pharmaceutically acceptable acids, and include for example those formed with inorganic acids e.g. hydrochloric, sulphuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid.
- Other non-pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of the compound of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- solvates and hydrates of the invention are also included within the scope of the invention.
- the conversion of a given compound salt to a desired compound salt is achieved by applying standard techniques, in which an aqueous solution of the given salt is treated with a solution of base e.g. sodium carbonate or potassium hydroxide, to liberate the free base which is then extracted into an appropriate solvent, such as ether. The free base is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt.
- base e.g. sodium carbonate or potassium hydroxide
- esters or amides of certain compounds of Formula I can be formed by treating those compounds having a free hydroxy or amino functionality with the acid chloride of the desired ester in the presence of a base in an inert solvent such as methylene chloride or chloroform.
- Suitable bases include triethylamine or pyridine.
- compounds of Formula I having a free carboxy group may be esterified using standard conditions which may include activation followed by treatment with the desired alcohol in the presence of a suitable base.
- compositions of the present invention are useful to inhibit or reduce undesirable neurotrophin activity both in vitro and in vivo.
- a composition comprising an effective amount of a compound of Formula I and a suitable carrier.
- suitable carrier is meant a carrier which admixes with the compound of Formula I to yield a composition suitable for the application for which it is to be used.
- effective amount is meant an amount of the compound sufficient to inhibit an undesired neurotrophin-mediated activity to a measurable extent, preferably by about 20%, more preferably by about 40%, most preferably by about 50%, as determined using assays of conventional design such as those described herein in the specific examples.
- the present composition has use as a media supplement to prevent undesirable neurotrophin-mediated activity of neuron cells in vitro.
- primary sensory neurons require NGF for survival in cell culture; however, NGF also influences neuron differentiation, notably process formation and outgrowth, which are undesirable for the use of primary sensory neurons in cell culture.
- NGF is added to the cell culture media along with the compound of Formula I.
- the compound is first combined with a carrier which will not adversely affect the growth of the cells in culture.
- Such carriers will include, for example, physiologically acceptable fluids such as water or any other fluid suitable for addition to the cell culture.
- the compound can be combined with media suitable for culturing neuronal cells prior to being added to the cell culture.
- concentration of the compound in the cell culture will be in the range of from about 1-500 ⁇ M, and preferably from about 1-100 ⁇ M.
- concentration of compound for use in preventing neuron differentiation in cell culture will, of course, vary depending on the extent of inhibition desired as well as the type of neuronal cells involved.
- compositions for in vivo administration e.g. for treating neurological conditions such as epilepsy or Alzheimer's disease, or for treating chronic pain
- Such compositions comprise a therapeutically effective amount of the compound of Formula I together with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means acceptable for use in the pharmaceutical and veterinary arts, i.e. non-toxic and not adversely affecting the activity of the compound.
- therapeutically effective amount means an amount of the compound sufficient to reduce undesirable neurotrophin-mediated activity, as determined using assays of conventional design, in an inflicted individual without causing adverse effects.
- compositions for in vivo administration include conventional carriers used in formulating drugs, such as diluents, excipients and the like. Reference may be made to “Remington's Pharmaceutical Sciences”, 17th Ed., Mack Publishing Company, Easton, Pa., 1985, for guidance on drug formulations generally. As will be appreciated, the pharmaceutical carriers used to prepare compositions in accordance with the present invention will depend on the dosage form to be used to treat the inflicted individual.
- a compound of Formula I is formulated for administration by injection intraventricularly, and is accordingly provided as an aqueous solution in sterile and pyrogen-free form and optionally buffered or made isotonic.
- the compound may be administered in distilled water or, more desirably, in saline or 5% dextrose solution.
- Water solubility of the compound of the invention may be enhanced, if desired, by incorporating into the composition a solubility enhancer, such as acetyltrimethylammonium bromide or chloride.
- Lyoprotectants such as mannitol, sucrose or lactose and buffer systems, such as acetate, citrate and phosphate may also be included in the formulation, as may bulking agents such as serum albumin.
- a pharmaceutical composition appropriate for treatment For use in treating individuals with a neurological condition, precise dosage sizes of a pharmaceutical composition appropriate for treatment are established in appropriately controlled trials, and will correspond to an amount of a compound of Formula I that reduces undesirable neurotrophin-mediated activity without causing intolerable side effects to the individual being treated. It is anticipated that an effective treatment regimen for patients will involve the intraventricular administration of dosages which achieve a level of the compound in the spinal fluid of the individual being treated of about 1-500 ⁇ M. It will be appreciated, of course, that the dosage sizes required to attain this in vivo concentration will vary according to the route of administration, the frequency of administration, on the individual being treated and on the neurological condition being treated.
- NGF was labelled using the Lactoperoxidase labelling method (Sutter et al., J. Biol. Chem., 1979) and the labelled NGF was separated from radiolabelling agents and free iodide using a PD-10 Sephadex G-25 column.
- PC12 cells were grown in RPMI with 10% heat inactivated donor horse serum and 5% fetal calf serum. Cells were harvested for binding by washing off the media with calcium-magnesium free balanced salt solution (Gey's solution) and incubated in 5 ml Gey's solution at 37° C. for 15 minutes.
- Gib's solution calcium-magnesium free balanced salt solution
- Hepes-Krebs Ringer buffer (10 mM Hepes pH7.35, containing 125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1 mg/ml BSA and 1.0 mg/ml glucose) at a concentration of 4 ⁇ 10 6 /ml and kept on ice.
- HLR Hepes-Krebs Ringer buffer
- the reaction was performed in a 96 well plate. Suspended cells (150 ul, 10 6 cells) were added to 125 I-NGF (final concentration of 0.5 nM) and the competing compound of Formual I in a final volume of 300 ul of HKR buffer. The plates were incubated with shaking for 2 hr at 4° C. At the end of the incubation, 100 ul aliquots of the reaction sample were added to 400 ul microcentrifuge tubes containing 200 ul of 10% glycerol in HKR buffer. The tubes were centrifuged for 1 minute at ⁇ 5000 rpm and the tip containing the cell pellet was cut off.
- Radioactivity bound to the cells was determined by measuring the 125 I-NGF associated with each pellet in a gamma counter. Specific binding is calculated as the difference between the amount of 125 I-NGF bound in the absence (total) and presence (NSB) of 50 nM unlabeled NGF. TrkA binding is determined similarly except 10 nM BDNF is added to all reactions. Table 1 summarizes the values obtained from this experiment for the inhibition of binding of NGF to P75 and TrkA by compounds of Formula I.
- the cell suspension was then preplated on a 100-mm Flacon culture dish and incubated for 45-60 min at 37° C. in a 5% CO 2 humidified atmosphere. Cells enriched in neurons were decanted for the bioassay, since non-neuronal cells of DRG preferentially stick to the culture substrate.
- tissue culture media admixed with a compound of Formula I was then added to test wells in duplicate to yield wells containing compound concentrations ranging from 0 ⁇ M-100 ⁇ M.
- 10 mL of Ham's F12 medium was added to duplicate NGF-containing wells. The plates were covered and incubated in the dark for 24-30 hrs. at 37° C. in a 5% CO 2 humidified atmosphere.
- Compound A N- ⁇ 5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione ⁇ -2-aminoethanol
- Nerve ligation injury was performed according to the method described by Kim and Chung (Pain 50: 355-363, 1992). Rats were anesthetized with halothane and the vertebrae over the L4 to S2 region were exposed. L5 and L6 spinal nerves were exposed, carefully isolated, tightly ligated with 4-0 silk suture distal to the DRG. After ensuring homeostatic stability, the wounds were sutured, and the animals were allowed to recover in the cages. Sham-operated rats were prepared in an identical fashion except that the L5/L6 nerve roots are not ligated.
- test compounds were injected through indwelling i. th. catheters. While under anesthesia, PE-10 tubing (8 cm) was inserted through an incision made in the atlanto-occipital membrane to the level of the lumbar enlargement of the rat and secured. Drug injections were made in a volume of 5 ⁇ l of 50% aqueous DMSO followed by a 9 ⁇ l saline flush.
- Thermal hyperalgesia was determined by focusing a radiant heat source onto the plantar surface of the affected paw of nerve-injured or sham-operated rats. Paw withdrawal latencies are determined by a photodetection device which halts the stimulus and the timer after a maximum cut-off of 40 sec to prevent tissue damage. The withdrawal latency of sham-operated rats were compared to those of ligated rats to measure the degree of hyperalgesia.
- Acute nociception was determined by using the nociceptive warm water tail-flick reflex. This test was performed by placing the tail of the nerve-injured or sham-operated rats in a heated water bath maintained at 55° C. The latency until tail withdrawal (rapid flick) from the bath was determined and compared among treatments. A 15 second cut-off was employed to avoid tissue damage.
- Compound A and morphine were tested in the nerve-ligated injury model of neuropathic pain using 3 routes of adminsitration: intrapertoneally (i.p.), intra-thecally (i.th.) and intracerebroventrically (i.c.v.). The compounds were evaluated for three endpoints: tactile allodynia, thermal hyperalgesia and acute nociception. Compound A is not active when given i.c.v. The results for i.p and i.th. administration are shown in Table 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/758,917 US20020169182A1 (en) | 1996-10-21 | 2001-01-11 | Neurotrophin antagonist compositions |
US11/179,610 US7291629B2 (en) | 1996-10-21 | 2005-07-13 | Neurotrophin antagonist compositions |
US11/905,406 US20080287484A1 (en) | 1996-10-21 | 2007-09-28 | Neurotrophin antagonist compositions |
US12/453,032 US20090215815A1 (en) | 1996-10-21 | 2009-04-28 | Neurotrophin antagonist compositions |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
GBGB9621902.7 | 1996-10-21 | ||
GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
GBGB9710904.5 | 1997-05-27 | ||
PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
US29245899A | 1999-04-15 | 1999-04-15 | |
US44050599A | 1999-11-15 | 1999-11-15 | |
US59201500A | 2000-06-12 | 2000-06-12 | |
US09/758,917 US20020169182A1 (en) | 1996-10-21 | 2001-01-11 | Neurotrophin antagonist compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US59201500A Continuation | 1996-10-21 | 2000-06-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/179,610 Division US7291629B2 (en) | 1996-10-21 | 2005-07-13 | Neurotrophin antagonist compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020169182A1 true US20020169182A1 (en) | 2002-11-14 |
Family
ID=26310264
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/758,917 Abandoned US20020169182A1 (en) | 1996-10-21 | 2001-01-11 | Neurotrophin antagonist compositions |
US11/179,610 Expired - Fee Related US7291629B2 (en) | 1996-10-21 | 2005-07-13 | Neurotrophin antagonist compositions |
US11/905,406 Abandoned US20080287484A1 (en) | 1996-10-21 | 2007-09-28 | Neurotrophin antagonist compositions |
US12/453,032 Abandoned US20090215815A1 (en) | 1996-10-21 | 2009-04-28 | Neurotrophin antagonist compositions |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/179,610 Expired - Fee Related US7291629B2 (en) | 1996-10-21 | 2005-07-13 | Neurotrophin antagonist compositions |
US11/905,406 Abandoned US20080287484A1 (en) | 1996-10-21 | 2007-09-28 | Neurotrophin antagonist compositions |
US12/453,032 Abandoned US20090215815A1 (en) | 1996-10-21 | 2009-04-28 | Neurotrophin antagonist compositions |
Country Status (14)
Country | Link |
---|---|
US (4) | US20020169182A1 (de) |
EP (1) | EP0930883B1 (de) |
JP (1) | JP2001503397A (de) |
KR (1) | KR20000052691A (de) |
AT (1) | ATE315397T1 (de) |
AU (1) | AU728523C (de) |
BR (1) | BR9712424A (de) |
CA (1) | CA2268450C (de) |
DE (1) | DE69735090T2 (de) |
DK (1) | DK0930883T3 (de) |
ES (1) | ES2257768T3 (de) |
IL (1) | IL129475A0 (de) |
NZ (1) | NZ335291A (de) |
WO (1) | WO1998017278A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
SK7012001A3 (en) * | 1998-11-25 | 2001-11-06 | Merck Patent Gmbh | Substituted benzo[de]isoquinoline-1,3-diones |
CA2352045A1 (en) * | 1998-11-25 | 2000-06-08 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Substituted benzo[de]isoquinoline-1,3-diones |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
MXPA05003502A (es) | 2002-10-08 | 2005-09-30 | Rinat Neuroscience Corp | Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo. |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ATE491444T1 (de) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
KR101504729B1 (ko) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물 |
GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
KR20080058403A (ko) * | 2005-09-15 | 2008-06-25 | 페인셉터 파마 코포레이션 | 뉴로트로핀 매개 활성 조절 방법 |
WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
EP2606894A1 (de) | 2011-12-20 | 2013-06-26 | Sanofi | Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
AU2019234213A1 (en) | 2018-03-12 | 2020-09-03 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
WO2023212596A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
US525841A (en) * | 1894-09-11 | Baling-press | ||
US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
US4006238A (en) * | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
ES459497A1 (es) * | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
DE3707651A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
US5420137A (en) * | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
CA2030129A1 (en) * | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
US5342942A (en) * | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
DE4232739A1 (de) * | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
IL110460A (en) * | 1993-08-18 | 2001-01-11 | Basf Ag | Bite-naphthalimides, their preparation and pharmaceutical preparations containing them |
US6291247B1 (en) * | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
GB9616105D0 (en) * | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
CA2279331C (en) | 1997-02-07 | 2010-04-20 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO1998052919A1 (fr) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Derives de phtalimide et produit pharmaceutique contenant ces derives |
WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
KR100364205B1 (ko) * | 1998-07-03 | 2002-12-11 | 다이호야쿠힌고교 가부시키가이샤 | 나프탈이미도벤즈아미드 유도체 또는 그의 염 |
US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
-
1997
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 EP EP97909098A patent/EP0930883B1/de not_active Expired - Lifetime
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Application Discontinuation
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en active IP Right Grant
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL129475A0 (en) | 2000-02-29 |
EP0930883A1 (de) | 1999-07-28 |
WO1998017278A1 (en) | 1998-04-30 |
EP0930883B1 (de) | 2006-01-11 |
DE69735090T2 (de) | 2006-09-14 |
JP2001503397A (ja) | 2001-03-13 |
US7291629B2 (en) | 2007-11-06 |
AU728523C (en) | 2001-08-09 |
CA2268450A1 (en) | 1998-04-30 |
AU728523B2 (en) | 2001-01-11 |
AU4696897A (en) | 1998-05-15 |
US20080287484A1 (en) | 2008-11-20 |
US20090215815A1 (en) | 2009-08-27 |
ATE315397T1 (de) | 2006-02-15 |
ES2257768T3 (es) | 2006-08-01 |
KR20000052691A (ko) | 2000-08-25 |
CA2268450C (en) | 2008-08-05 |
NZ335291A (en) | 2001-02-23 |
BR9712424A (pt) | 2001-11-20 |
DE69735090D1 (de) | 2006-04-06 |
US20050250807A1 (en) | 2005-11-10 |
DK0930883T3 (da) | 2006-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7291629B2 (en) | Neurotrophin antagonist compositions | |
US6492380B1 (en) | Method of inhibiting neurotrophin-receptor binding | |
US6468990B1 (en) | Method of inhibiting binding of nerve growth factor to p75 NTR receptor | |
DE69933573T2 (de) | Chinazolinderivate als medikamente | |
US6448257B1 (en) | Compounds and methods to treat cardiac failure and other disorders | |
DE69811492T2 (de) | Benzonaphthyridine | |
JP2877231B2 (ja) | スピロキヌクリジン誘導体の光学異性体、それらの製造法、それらからなる薬剤組成物およびそれらを使用した治療法 | |
US5434177A (en) | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | |
MXPA99003637A (es) | Composiciones antagonistas de las neurotrofinas | |
US5580877A (en) | Pyrazolo-quinoline derivatives for treating cerebral ischemia | |
EA011255B1 (ru) | Производные 2-аминобензойной кислоты | |
US6057334A (en) | Benzo[g]quinoline derivatives | |
IL107001A (en) | History of acridinamino and pharmaceutical preparations containing them | |
KR0172971B1 (ko) | 1,2,3,3a,8,8a-헥사히드로-1,3a,8-트리메틸 피롤로[2,3-b]인돌의 테트라히드로 이소퀴놀리닐 카바메이트 | |
WO2008100450A4 (en) | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury | |
WO2016190616A1 (ko) | 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도 | |
EA001658B1 (ru) | Хиноксалиндионы | |
AU2005201951C1 (en) | Method of inhibiting neurotrophin-receptor binding | |
JP2000505425A (ja) | Trhを用いるベータ―アミロイドペプチドに関連する状態の処置方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALLELIX BIOPHARMACEUTICALS INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TEHIM, ASHOK;CHEN, XIANNONG;REEL/FRAME:015011/0957;SIGNING DATES FROM 19990413 TO 19990414 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |